CRNX: Crinetics Pharma Company Value to Net Income

Compliance with eco-standards in Crinetics Pharmaceuticals laboratories impacts process stability, which is reflected in the company's P/E ratio dynamics. The value -17.70 indicates the current level of the multiple. Fundamentals rely on the development of acromegaly treatments and investments, while strict FDA control and R&D costs create significant barriers to entry for competitors in the endocrine sector.

P/E Multiple: Crinetics Pharma (CRNX) for 07/04/2022 - 09/12/2026

Comprehensive metric breakdowns and analytics for Crinetics Corp (CRNX)

- price and consensus price forecast:

Stock Price Crinetics Pharma|CRNX - Consensus Target

- market capitalization information:

Market Value Crinetics Pharma|CRNX - Total Company Value

- balance sheet net asset value indicators:

Accounting Value per Share Crinetics|CRNX - Book Capitalization|Market-to-Book Ratio crinetics.com|CRNX - Cumulative Company Assets

- company liabilities and liquidity data:

- company profitability and valuation multiples indicators:

CRNX - Net Profit|Company Profit Forecast Crinetics Pharmaceuticals|CRNX - Price to Earnings Ratio|Market Cap to Projected Earnings Crinetics Corp|CRNX - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Ratio Crinetics Pharmaceuticals, Inc.|CRNX - Operating profit EBITDA|Net earnings per share for the last 12 months Crinetics|CRNX - Earnings per share for the last twelve months|Year-over-year earnings per one share growth for the last 12 months crinetics.com|CRNX - Earnings growth in current year|Consensus forecast of earnings per share growth for next year Crinetics Pharmaceuticals

- company sales and revenue statistics:

CRNX - Company Revenue|Company Revenue Forecast Crinetics|CRNX - P/S Multiple|Market Cap to Future Revenue Ratio Crinetics Corp|CRNX - Revenue Growth YoY (Last 12 Months)

Summary company analysis:Crinetics Pharmaceuticals, Inc.

The development of the innovative portfolio at Crinetics Pharmaceuticals (CRNX) creates growth potential, although high drug development costs increase reliance on external capital. The price-to-earnings ratio measures the extent to which investors are overpaying for future earnings, which, via the monthly P/E dynamics of the company on the GURU.Markets platform, allows for an assessment of the risk of capital losses amid clinical trial volatility.

Analysis of competing companies